PORT study

The phase 2 PORT study is an open-label, randomized, cross-over study which compares safety, tolerability and efficacy, of peripheral or central intravenous administration of melflufen in combination with dexamethasone in patients with relapsed refractory multiple myeloma.

Up to 25 patients who have received at least two prior lines of therapy will be enrolled. The study is expected to be fully recruited in December 2020, and top line results may be presented in Q1 2021.